While these results might suggest reduced translational potential of CRHR1 antagonists for the treatment of anxiety and other mental health disorders, it is important to consider that the drug administration in humans was not specific to a particular brain region, which is a notable difference from preclinical models. This evidence concerns the gene CRHR1 and Anxiety.